Tad works with BCG clients on non-financial risk & compliance topics, including target operating models, risk management culture, organizational design, and crisis management and remediation. He also advises on some of the most salient, cutting-edge risk issues including responsible use of AI, incorporating geopolitical risk into operational management, cyber security, and many others. Tad is the senior sponsor for the firm’s Global Data organization, which oversees and drives the creation of foundational data capabilities and assets across the enterprise.

For more than 10 years, Tad served as BCG’s Chief Risk Officer (CRO), building the structures, processes, and teams necessary to enhance our organization’s focus on risk and compliance management as the firm and world grew more complex. During his tenure, he sat on the firm’s Audit and Risk Committee; its Digital Investment Committee; the Operational Leadership Team; and led the Global Risk Management function, the Data Privacy Office, and cyber security group. Externally, Tad was a member of the World Economic Forum’s CRO community and World 50.

Prior to becoming CRO, Tad engaged with biopharmaceutical clients driving change efforts focused on organizational design, integration and transformation. These programs involved all aspects of the organization including R&D and Sales & Marketing, among other enabling functions. During this time, Tad founded BCG’s internal Operational Innovations group, which is focused on driving and accelerating large change programs within BCG's internal functions. He also started the firm’s New Jersey office and served as the Office Leader for five years.

Tad has a B.A. in Economics from Dartmouth College and an MBA from Stanford University Graduate School of Business. Outside of BCG, Tad lives with his family in Montclair, NJ, and enjoys photography, his three dogs, Boston sports teams, and golf.

In his 18 years of client service at BCG, much of Tad's work has focused on biopharmaceutical change efforts, especially organizational design, integration, and transformation. These programs involved all aspects of the biopharma value chain including R&D, sales and marketing, and various enabling functions.

In 2015, Tad founded BCG's internal operational innovations group, designed to drive and accelere large change programs within BCG's internal functions.

Before joining the firm, Tad was a consultant with the LEK Partnership, developing M&A and corporate strategy on the health care, telecommunications, and media industries.


  • MBA, Arjay Miller Scholar, Stanford University Graduate School of Business
  • BA, phi beta kappa, economics, Dartmouth College